top of page

Merck to offer Provantage end-to-end development and manufacturing services to Y-mAbs

Merck will provide its Provantage End-to-End development and manufacturing services to Y-mAbs Therapeutics in support of Y-mAbs' monoclonal antibody in late stage clinical development.

Click on this link for more information.

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page